AKCEA THERAPEUTICS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation
Amortization of right-of-use operating lease assets
Amortization of intangibles
Amortization of discount/premium on investment securities, net
Non-cash interest expense for line of credit with Ionis Pharmaceuticals, Inc.
Non-cash sublicensing expense
Stock-based compensation expense
Changes in operating assets and liabilities:
Contracts receivable
Accounts receivable
Other current and long-term assets
Inventory
Accounts payable
Receivable/payable to Ionis Pharmaceuticals, Inc.
Long-term income tax receivable
Accrued compensation
Deferred rent
Accrued liabilities
Income taxes payable
Deferred revenue
Net cash provided by (used in) operating activities
Investing activities:
Purchases of short-term investments
Proceeds from maturity of short-term investments
Purchase of property, plant and equipment
Net cash provided by (used in) investing activities
Financing activities:
Proceeds from issuance of Series A convertible preferred stock to Ionis Pharmaceuticals, Inc.
Proceeds from issuance of common stock, net of underwriters' discounts
Proceeds from exercise of common stock options and employee stock purchase plan issuances
Payments of tax withholdings related to exercise of employee stock awards
Distribution to Ionis Pharmaceuticals, Inc.
Proceeds from issuance of common stock to Ionis Pharmaceuticals in TTR transaction
Proceeds from issuance of common stock, net of underwriters' discount
Proceeds from line of credit from Ionis Pharmaceuticals, Inc.
Offering costs paid
Net cash (used in) provided by financing activities
Effect of exchange rates on cash
Cash and cash equivalents
Net increase in cash and cash equivalents
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures of non-cash investing and financing activities:
Unpaid deferred offering costs
Right-of-use assets obtained in exchange for lease liabilities
Purchase of property, plant and equipment included in accounts payable
Purchase of property, plant and equipment included in long-term deferred rent liability
Acquisition of research and development licenses and milestone payments
Capital contribution from Ionis Pharmaceuticals, Inc.
Conversion of preferred stock to common stock upon initial public offering
Conversion of line of credit from Ionis Pharmaceuticals, Inc. into common stock
Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets:
Cash and cash equivalents
Restricted cash included in deposits and other assets

Comments